ScreenerHero

PRLD Prelude Therapeutics Incorporated

NAS · US · Healthcare · Biotechnology · preludetx.com
3.830USD+0.52%Mkt Cap: 305.04M $P/E: —

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver m…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap305.04M USD
Enterprise Value258.30M USD
Revenue (TTM)22.42M USD
Gross Profit22.42M USD
Net Income (TTM)-99.50M USD
Revenue/Share0.27 USD
Last Price3.830 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees79
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.93
PEG—
EV/EBITDA-4.00
EV/Revenue11.52
P/S13.53
P/B2.93
EPS (TTM)-0.73
EPS (Forward)-0.55
52W Range
1.04048% of range6.830
52W High6.830 USD
52W Low1.040 USD
Profitability
Gross Margin100.00%
Oper. Margin-270.93%
EBITDA Margin-287.68%
Profit Margin-819.59%
ROE-144.96%
ROA-70.41%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-56.30M USD
CapEx (TTM)67.00K USD
FCF Margin-61.74%
FCF Yield-4.54%
Net Debt-134.11M USD
Net Debt/EBITDA2.08
Balance Sheet
Debt/Equity0.26
Current Ratio4.07
Quick Ratio3.99
Book Value/Sh1.30 USD
Cash/Share1.47 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.200 USD
Upside (mean)+140.2%
Target Range6.000 USD – 12.00 USD
6.000+140.2% to mean12.00
# Analysts5
Ownership
Shares Out.64.92M
Float22.06M
Insiders13.76%
Institutions76.42%
Short Interest
Short Ratio6.8d
Short % Float14.33%
Short % Out.4.54%
Shares Short3.63M
Short (prev mo.)3.82M
Technical
SMA 504.981 (-23.1%)
SMA 2003.894 (-1.6%)
Beta0.96
S&P 52W Chg16.45%
Avg Vol (30d)502.16K
Avg Vol (10d)573.03K
Technical Indicators
RSI (14)36.1
MACD-0.3565
MACD Signal-0.3041
MACD Hist.-0.0523
BB Upper5.464 USD
BB Middle4.338 USD
BB Lower3.213 USD
BB Width51.89%
ATR (14)0.3268 USD
Vol Ratio (20d)0.88x